An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

Trial Profile

An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Age-related macular degeneration
  • Focus Adverse reactions
  • Acronyms ReCLAIM
  • Sponsors Stealth BioTherapeutics
  • Most Recent Events

    • 07 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
    • 07 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.
    • 14 Nov 2016 Top-line data are expected mid-year 2017, as per a Stealth BioTherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top